How to buy Checkmate Pharmaceuticals stock

Checkmate Pharmaceuticals, Inc is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 22 staff and has a market cap (total outstanding shares value) of 0.00.

Checkmate Pharmaceuticals share price

Use our graph to track the performance of CMPI stocks over time.

Checkmate Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$5.84 - $23.10
50-day moving average	$10.60
200-day moving average	$12.80
Wall St. target price	$24.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Checkmate Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Checkmate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Checkmate Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkmate Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-33.38%
Return on equity TTM	-59.2%
Profit margin	0%
Book value	N/A
Market capitalisation	$136.4 million

TTM: trailing 12 months

Shorting Checkmate Pharmaceuticals shares

There are currently 231,230 Checkmate Pharmaceuticals shares held short by investors – that's known as Checkmate Pharmaceuticals's "short interest". This figure is 27.4% up from 181,536 last month.

There are a few different ways that this level of interest in shorting Checkmate Pharmaceuticals shares can be evaluated.

Checkmate Pharmaceuticals's "short interest ratio" (SIR)

Checkmate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Checkmate Pharmaceuticals shares currently shorted divided by the average quantity of Checkmate Pharmaceuticals shares traded daily (recently around 86928.571428571). Checkmate Pharmaceuticals's SIR currently stands at 2.66. In other words for every 100,000 Checkmate Pharmaceuticals shares traded daily on the market, roughly 2660 shares are currently held short.

However Checkmate Pharmaceuticals's short interest can also be evaluated against the total number of Checkmate Pharmaceuticals shares, or, against the total number of tradable Checkmate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkmate Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Checkmate Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0169% of the tradable shares (for every 100,000 tradable Checkmate Pharmaceuticals shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkmate Pharmaceuticals.

Find out more about how you can short Checkmate Pharmaceuticals stock.

Checkmate Pharmaceuticals share dividends

We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.

Checkmate Pharmaceuticals overview

Checkmate Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

• What percentage of Checkmate Pharmaceuticals is owned by insiders or institutions?

  Currently 4.719% of Checkmate Pharmaceuticals shares are held by insiders and 85.709% by institutions.

• How many people work for Checkmate Pharmaceuticals?

  Latest data suggests 22 work at Checkmate Pharmaceuticals.

• When does the fiscal year end for Checkmate Pharmaceuticals?

  Checkmate Pharmaceuticals's fiscal year ends in December.

• Where is Checkmate Pharmaceuticals based?

  Checkmate Pharmaceuticals's address is: 245 Main Street, Cambridge, MA, United States, 02142

• What is Checkmate Pharmaceuticals's ISIN number?

  Checkmate Pharmaceuticals's international securities identification number is: US1628181083